DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:


Dosimetry for 125I radioactive seed implantation therapy for hepatocellular carcinoma
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    Abstract:

    Hepatocellular carcinoma (HCC) is an aggressive malignancy. Early lesions respond well to hepatic resection or liver transplantation. However, only a few of HCC patients are suitable for surgical intervention. External beam radiation and chemotherapy is poorly efficacious. In the last 20 years, HCCs belonging to the radiosensitive tumor group has been confirmed. Along with the development of new radiotherapy technology and facilities, the research about brachytherapy(especially 125I seed implantation therapy) has provoked more interests in the world. Radioactive seed implantation therapy is a form of interstitial brachytherapy, with the property of local “conformal radiotherapy” and the advantages of minimal invasion, convenience, high performance, and minimal adverse effects. It is a promising therapy for HCC, however the dosimetry hasn′t yet been identified and lacks verification in prospective research. This report aims to further explore the best prescription dose and radioactivity for 125I interstitial implantation brachytherapy for HCC.

    参考文献
    相似文献
    引证文献
引用本文

Jin Lü,Xiufeng Cao.[J].南京医科大学学报(自然科学版),2008,28(5):269-272

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2008-08-26
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期:
  • 出版日期:
通知关闭
郑重声明